Fabrication, characterization, and in vitro biological evaluation of glycyrrhetinic acid ligand-functionalized proliposomes encapsulated docetaxel for treatment of hepatocellular carcinoma

IF 4.9 2区 化学 Q2 CHEMISTRY, PHYSICAL
Yuan Lin , Chuangnan Li , Kaijie Cen , Jucai Xu , Jing Chen
{"title":"Fabrication, characterization, and in vitro biological evaluation of glycyrrhetinic acid ligand-functionalized proliposomes encapsulated docetaxel for treatment of hepatocellular carcinoma","authors":"Yuan Lin ,&nbsp;Chuangnan Li ,&nbsp;Kaijie Cen ,&nbsp;Jucai Xu ,&nbsp;Jing Chen","doi":"10.1016/j.colsurfa.2024.135802","DOIUrl":null,"url":null,"abstract":"<div><div>Docetaxel (DTX) is a chemotherapeutic drug extracted from the needles of Taxus baccata with a broad anticancer spectrum that has been widely used for the treatment of various cancers. However, its high hydrophobicity and poor solubility results in low bioavailability that restricted clinical application. To circumvent these challenges, the present investigation was performed to develop DTX proliposomes mediated glycyrrhetinic acid ligand (glycyrrhetinic acid - diaminododecane - cholestrol, GADC) for the treatment of hepatocellular carcinoma. The optimal parameters of liposome formulation were egg phosphatidylcholine/cholesterol mass ratio of 9:1, the ratio of DTX to lipid substance within 1/10, the percent of GADC ligand (8 %), hydration time of 30 min and homogenization time of 10 min. To protect DTX liposomes from external environment during their storage, DTX proliposomes mediated GADC (GADC-DTX-PL), three optimum processing variables, lyoprotectants of sucrose and mannitol, the sucrose/mannitol ratio of 1:1, and the lyoprotectant/egg phosphatidylcholine of 8:1, were obtained after investigation. Under the optimum lyophilization conditions, GADC-DTX-PL was prepared and reconstituted proliposomes were determined to evaluate its physicochemical characterizations. These proliposomes showed that GADC-DTX-PL were spherical particles with an average size of 214.88 ± 11.00 nm, PDI value of 0.23 ± 0.00, zeta potential of –20.04 ±4.94 mV, encapsulation efficiency of 80.58 ± 0.91 %, and drug loading of 7.39 %. In addition, encapsulation of DTX in proliposomal formulation resulted in stable and slow drug release. Furthermore, <em>in vitro</em> bioactivity was evaluated, cytotoxicity effect and apoptosis efficiency of GADC-DTX-PL by HepG2 cells was significantly higher than that of DTX proliposomes without GADC. In the cell cycle assay, the results confirmed that the effect of GADC-DTX-PL regarding the initiation of apoptosis is accompanied with adjustment in the cell cycle progress via generating G2/M arrest. This potential of this novel approach for delivery DTX to hepatocellular cells lies in the ability to combine a targeted ligand of GADC and proliposomes simultaneously. Such formulation of GADC-DTX-PL enhances the selectivity of DTX delivery to hepatocellular cells, thereby improving the efficacy of chemotherapy.</div></div>","PeriodicalId":278,"journal":{"name":"Colloids and Surfaces A: Physicochemical and Engineering Aspects","volume":"707 ","pages":"Article 135802"},"PeriodicalIF":4.9000,"publicationDate":"2024-11-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Colloids and Surfaces A: Physicochemical and Engineering Aspects","FirstCategoryId":"92","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0927775724026669","RegionNum":2,"RegionCategory":"化学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CHEMISTRY, PHYSICAL","Score":null,"Total":0}
引用次数: 0

Abstract

Docetaxel (DTX) is a chemotherapeutic drug extracted from the needles of Taxus baccata with a broad anticancer spectrum that has been widely used for the treatment of various cancers. However, its high hydrophobicity and poor solubility results in low bioavailability that restricted clinical application. To circumvent these challenges, the present investigation was performed to develop DTX proliposomes mediated glycyrrhetinic acid ligand (glycyrrhetinic acid - diaminododecane - cholestrol, GADC) for the treatment of hepatocellular carcinoma. The optimal parameters of liposome formulation were egg phosphatidylcholine/cholesterol mass ratio of 9:1, the ratio of DTX to lipid substance within 1/10, the percent of GADC ligand (8 %), hydration time of 30 min and homogenization time of 10 min. To protect DTX liposomes from external environment during their storage, DTX proliposomes mediated GADC (GADC-DTX-PL), three optimum processing variables, lyoprotectants of sucrose and mannitol, the sucrose/mannitol ratio of 1:1, and the lyoprotectant/egg phosphatidylcholine of 8:1, were obtained after investigation. Under the optimum lyophilization conditions, GADC-DTX-PL was prepared and reconstituted proliposomes were determined to evaluate its physicochemical characterizations. These proliposomes showed that GADC-DTX-PL were spherical particles with an average size of 214.88 ± 11.00 nm, PDI value of 0.23 ± 0.00, zeta potential of –20.04 ±4.94 mV, encapsulation efficiency of 80.58 ± 0.91 %, and drug loading of 7.39 %. In addition, encapsulation of DTX in proliposomal formulation resulted in stable and slow drug release. Furthermore, in vitro bioactivity was evaluated, cytotoxicity effect and apoptosis efficiency of GADC-DTX-PL by HepG2 cells was significantly higher than that of DTX proliposomes without GADC. In the cell cycle assay, the results confirmed that the effect of GADC-DTX-PL regarding the initiation of apoptosis is accompanied with adjustment in the cell cycle progress via generating G2/M arrest. This potential of this novel approach for delivery DTX to hepatocellular cells lies in the ability to combine a targeted ligand of GADC and proliposomes simultaneously. Such formulation of GADC-DTX-PL enhances the selectivity of DTX delivery to hepatocellular cells, thereby improving the efficacy of chemotherapy.
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
8.70
自引率
9.60%
发文量
2421
审稿时长
56 days
期刊介绍: Colloids and Surfaces A: Physicochemical and Engineering Aspects is an international journal devoted to the science underlying applications of colloids and interfacial phenomena. The journal aims at publishing high quality research papers featuring new materials or new insights into the role of colloid and interface science in (for example) food, energy, minerals processing, pharmaceuticals or the environment.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信